Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model

Ellen Van Van Gulck,Nádia Conceição-Neto,Liese Aerts,Wim Pierson,Lore Verschueren,Mara Vleeschouwer,Vinod Krishna,Isabel Nájera,Frederik Pauwels

DOI: https://doi.org/10.3390/v16030347

2024-02-24

Viruses

Abstract:Background and Aims: Treatment with siRNAs that target HBV has demonstrated robust declines in HBV antigens. This effect is also observed in the AAV-HBV mouse model, which was used to investigate if two cycles of GalNAc-HBV-siRNA treatment could induce deeper declines in HBsAg levels or prevent rebound, and to provide insights into the liver immune microenvironment. Methods: C57Bl/6 mice were transduced with one of two different titers of AAV-HBV for 28 days, resulting in stable levels of HBsAg of about 103 or 105 IU/mL. Mice were treated for 12 weeks (four doses q3wk) per cycle with 3 mg/kg of siRNA-targeting HBV or an irrelevant sequence either once (single treatment) or twice (retreatment) with an 8-week treatment pause in between. Blood was collected to evaluate viral parameters. Nine weeks after the last treatment, liver samples were collected to perform phenotyping, bulk RNA-sequencing, and immunohistochemistry. Results: Independent of HBsAg baseline levels, treatment with HBV-siRNA induced a rapid decline in HBsAg levels, which then plateaued before gradually rebounding 12 weeks after treatment stopped. A second cycle of HBV-siRNA treatment induced a further decline in HBsAg levels in serum and the liver, reaching undetectable levels and preventing rebound when baseline levels were 103 IU/mL. This was accompanied with a significant increase in inflammatory macrophages in the liver and significant upregulation of regulatory T-cells and T-cells expressing immune checkpoint receptors. Conclusions: Retreatment induced an additional decline in HBsAg levels, reaching undetectable levels when baseline HBsAg levels were 3log10 or less. This correlated with T-cell activation and upregulation of Trem2.

virology

What problem does this paper attempt to address?

### What problem does this paper attempt to solve?

This paper aims to explore whether repeated use of HBV siRNA treatment in an AAV-HBV mouse model can further reduce Hepatitis B surface antigen (HBsAg) levels and prevent rebound, while also studying the impact of this treatment on the liver immune microenvironment.

#### Specific Objectives:
1. **Evaluate the effect of repeated treatment**: Investigate whether a second round of the same HBV siRNA treatment after the first round can further reduce HBsAg levels and prevent its rebound.
2. **Explore changes in the immune microenvironment**: Using methods such as gene sequencing, study the specific impact of repeated treatment on the liver immune microenvironment, particularly changes in immune cells such as macrophages, regulatory T cells, and T cells expressing immune checkpoint receptors.

Through these studies, the paper hopes to provide new strategies and insights for the functional cure of chronic hepatitis B (CHB).